Aloe Therapeutics, Inc

Aloe Therapeutics is aimed at delivering cancer cures.  We have designed a new class of locally delivered immunotherapy, akin to an in situ vaccine, called Allo-Immunotherapy (AIM).  AIM is implanted at the tumor site to trigger an influx of immune cells in the tumor microenvironment - turning "cold" , immune deficient tumors into "hot" immune rich tumors, and to turn "hot" tumors "hotter". AIM will be positioned as a partner of choice for checkpoint immunotherapy combinations to increase  increase response rates, extend durability of response, and to expand eligibility for patients with "cold" tumors and limited treatment options. INFLAME WITH AIM